摘要
中药苷类化合物治疗骨不愈合的机制主要包括促进成骨细胞分化、抑制破骨细胞生成、促进新生血管生成、抑制炎症反应等,能够通过多途径、多靶点和多效性的治疗策略,实现促进骨质生成与抑制骨质破坏等多重目标.但目前研究仍存在诸多不足,如机制研究不够深入、缺乏大规模临床试验、药物递送系统不完善、未充分考虑个体差异以及长期不良反应不明确等.今后,应深入探索其分子机制,开展临床试验验证疗效和安全性,改进药物递送系统,考虑个体化治疗,评估长期不良反应,并探索与其他治疗方法的联合应用,为临床治疗骨折不愈合开辟新的策略和视角.
Abstract
The mechanisms by which glycoside compounds of Chinese medicinals treat bone nonunion include promoting osteoblast dif-ferentiation,inhibiting osteoclast formation,enhancing angiogenesis,and reducing inflammatory responses,etc.These compounds achieve multiple therapeutic objectives through multi-pathway,multi-target,and multi-efficacy strategies to promote bone formation and inhibit bone destruction,etc.However,current research faces limitations,such as insufficient depth in mechanistic studies,lack of large-scale clinical trials,inadequate drug delivery systems,lack of consideration for individual variability,and unclear long-term side effects.Future studies should focus on in-depth exploration of molecular mechanisms,clinical trials to validate efficacy and safety,improvements in drug delivery systems,personalized treatments,evaluation of long-term side effects,and potential integration with other therapies.These efforts may open new strategies and perspectives for clinical treatment of bone nonunion.
国家科技期刊平台
NSTL
万方数据